Development · 6 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
The United States Food and Drug Administration (USFDA) inspected Cohance Lifesciences' formulation plant located at Shamshabad, Telangana, from August 27 to September 4, 2026, and the inspection concluded with the issuance of a Form FDA 483 containing four observations.
Cohance Lifesciences announced that the United States Food and Drug Administration (USFDA) inspected the Company's formulation plant located at Shamshabad, Telangana, from 27 August to 4 September 2026.
The United States Food and Drug Administration (US FDA) issued a Form FDA 483 with four observations to Cohance Lifesciences' formulation plant in Telangana.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.